From portfolio management services (PMS) and alternative investment funds (AIFs) to private credit, these asset classes offer the potential...

The Indian Pharmaceutical Alliance seeks to regularize many drugs. These drugs have been marketed for years without central approval. Examp...

India and Uzbekistan aim to double bilateral trade to three billion dollars within three years. Businesses are urged to increase investment...

Exports from special economic zones experienced a remarkable boost in 2025-26, eclipsing USD 185 billion. The pharmaceutical industry also ...

India's pharmaceutical industry is expected to reach$80-90 billion by 2030, well below its earlier$130 billion target, as U.S. tariff uncer...

Indian equities rallied sharply as easing oil prices following renewed US-Iran talks boosted sentiment. Sensex gained 544 points and Nifty ...

The Nifty index is approaching a critical juncture after a prolonged consolidation period. Foreign institutional investors are showing earl...

The ethanol story started simply enough: Cut India's dependence on imported crude oil. It would save foreign exchange. Give farmers a new a...

The Indian stock market rallied around 3% over the last week, recouping its early losses despite global volatility. Analysts expect the mar...

Several Indian family businesses received awards for their significant contributions. Serum Institute of India was honored for philanthropi...

Pharma mutual funds are leading returns in CY2026, driven by strong earnings, defensive demand, and US export growth. Despite recent outper...

US pharma tariffs: Experts have urged a shift towards global diversification and prioritising innovation for Indian pharma to lessen market...

India's pharma and healthcare sector recorded 65 deals worth $13.9 billion in Q2 CY2026, with volumes falling 17% quarter-on-quarter to a f...

US President Trump's proposed tariffs on imported generic drugs will not immediately affect Indian drugmakers. Indian companies export sign...

US President Donald Trump's proposed tariffs of up to 200% on imported generic medicines could put pressure on India's pharmaceutical expor...

Trump's generic drug tariffs plan provides Indian drugmakers a two-year duty-free window. This allows companies time to reassess manufactur...

For Indian exporters, the two-year tariff-free period offers additional time to reassess supply chains and investment plans. While the imme...